

Anja Mottok

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8677005/publications.pdf>

Version: 2024-02-01

21
papers

1,550
citations

686830

13
h-index

839053

18
g-index

22
all docs

22
docs citations

22
times ranked

2622
citing authors

#	ARTICLE	IF	CITATIONS
1	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. <i>Lancet Oncology</i> , 2015, 16, 1111-1122.	5.1	483
2	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 190-201.	0.8	257
3	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. <i>PLoS Medicine</i> , 2016, 13, e1002197.	3.9	185
4	Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. <i>Journal of Experimental Medicine</i> , 2016, 213, 1881-1900.	4.2	143
5	Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. <i>Blood</i> , 2017, 129, 2760-2770.	0.6	112
6	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 440-459.	7.7	103
7	Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1125-1130.	3.3	49
8	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. <i>Nature Medicine</i> , 2020, 26, 577-588.	15.2	46
9	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. <i>Blood</i> , 2018, 131, 226-235.	0.6	31
10	Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD. <i>Blood</i> , 2015, 126, 437-444.	0.6	29
11	Validation of the <scp>MCL</scp>35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. <i>British Journal of Haematology</i> , 2019, 184, 616-624.	1.2	25
12	The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1208-1213.	2.0	25
13	Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. <i>Blood</i> , 2021, 137, 2196-2208.	0.6	18
14	Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	15
15	Convergence of risk prediction models in follicular lymphoma. <i>Haematologica</i> , 2019, 104, e252-e255.	1.7	9
16	Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. <i>Annals of Hematology</i> , 2021, 100, 1537-1546.	0.8	7
17	Non-Invasive Bioluminescence Imaging to Monitor the Immunological Control of a Plasmablastic Lymphoma-Like B Cell Neoplasia after Hematopoietic Cell Transplantation. <i>PLoS ONE</i> , 2013, 8, e81320.	1.1	6
18	A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2020, 11, 593321.	2.2	4

#	ARTICLE	IF	CITATIONS
19	Methotrexate-induced lymphoproliferative disorders: regression matters. <i>Leukemia and Lymphoma</i> , 2018, 59, 1027-1029.	0.6	1
20	Activated Ral and Mutated RAS Are Independent Drivers of Multiple Myeloma Cell Survival.. <i>Blood</i> , 2018, 132, 3217-3217.	0.6	0
21	Tissue Derived Non-Classical Monocyte Derived Host Macrophages Protect Against Murine Intestinal Acute Graft-Versus-Host Disease. <i>Blood</i> , 2018, 132, 3315-3315.	0.6	0